Nancy E Davidson

List of Publications by Year
in descending order

235 papers	45,683 citations	4831 87 h-index	2108 210 g-index
243 all docs	243 docs citations	243 times ranked	40272 citing authors

#	Article	IF	Citations
1	Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2022, 40, 2612-2635.	0.8	60
2	Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. Cancer Investigation, 2021, 39, 21-24.	0.6	1
3	Selection of Adjuvant Endocrine Therapy for Women with Breast Cancer in Menopausal Transition: Is It Simpler than We Thought?. Journal of the National Cancer Institute, 2021, 113, 1444-1446.	3.0	1
4	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 3938-3958.	0.8	40
5	Optimal adjuvant endocrine therapy for breast cancer. Lancet Oncology, The, 2021, 22, 1357-1358.	5.1	6
6	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology, 2020, 6, 505.	3.4	51
7	Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma. Scientific Reports, 2020, 10, 11487.	1.6	16
8	The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility. Clinical Cancer Research, 2020, 26, 5543-5545.	3.2	6
9	Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study. Cancer, 2020, 126, 5239-5246.	2.0	1
10	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene, 2019, 38, 390-405.	2.6	149
11	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nature Communications, 2019, 10, 5114.	5.8	64
12	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2019, 37, 3152-3165.	0.8	117
13	Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era. Journal of the National Cancer Institute, 2019, 111, 641-643.	3.0	2
14	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€“Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2019, 37, 423-438.	0.8	384
15	Gonadotropin-Releasing Hormone (GnRH) Agonists for Fertility Preservation: Is POEMS the Final Verse?. Journal of the National Cancer Institute, 2019, 111, 107-108.	3.0	1
16	HDAC5â€“LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. International Journal of Cancer, 2018, 143, 1388-1401.	2.3	54
17	Searching for the IDEAL Duration of Adjuvant Endocrine Therapy. Journal of the National Cancer Institute, 2018, 110, 6-8.	3.0	5
18	Incident Cancer in Cancer Survivorsâ€”When Cancer Lurks in the Background. JAMA Oncology, 2018, 4, 836.	3.4	1

#	Article	IF	Citations
19	Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth. Journal of Biological Chemistry, 2018, 293, 1120-1137.	1.6	55
20	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 2804-2807.	0.8	93
21	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary. Journal of Oncology Practice, 2018, 14, 501-504.	2.5	24
22	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 2736-2740.	0.8	141
23	Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. Scientific Reports, 2018, 8, 17313.	1.6	22
24	AACR White Paper: Shaping the Future of Cancer Prevention â€“ A Roadmap for Advancing Science and Public Health. Cancer Prevention Research, 2018, 11, 735-778.	0.7	36
25	Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Research, 2018, 78, 6209-6222.	0.4	58
26	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 2018, 379, 122-137.	13.9	448
27	Optimal duration of trastuzumab for early HER2-positive breast cancer. Lancet, The, 2017, 389, 1167-1168.	6.3	1
28	Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncology, 2017, 3, 666.	3.4	135
29	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clinical Cancer Research, 2017, 23, 2691-2701.	3.2	106
30	Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clinical Cancer Research, 2017, 23, 43-51.	3.2	73
31	New Strategies in Metastatic Hormone Receptorâ€“Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. Clinical Cancer Research, 2017, 23, 1126-1131.	3.2	11
32	Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncology, The, 2017, 18, e653-e706.	5.1	153
33	A metastasis biomarker (MetaSite Breastâ„¢ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. Npj Breast Cancer, 2017, 3, 42.	2.3	48
34	Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Research, 2017, 19, 60.	2.2	116
35	Practical Approach to Triple-Negative Breast Cancer. Journal of Oncology Practice, 2017, 13, 293-300.	2.5	63
36	Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. Oncotarget, 2017, 8, 81737-81753.	0.8	34

#	Article	IF	Citations
37	Conquering Metastatic Breast Cancer. Journal of Oncology Practice, 2016, 12, 11-12.	2.5	1
38	Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 23-32.	1.8	20
39	Targeting tumorigenicity of breast cancer stem-like cells using combination epigenetic therapy: something old and something new. Journal of Thoracic Disease, 2016, 8, 2971-2974.	0.6	6
40	Reply to C. Shah et al. Journal of Clinical Oncology, 2016, 34, 1824-1825.	0.8	0
41	AACR Cancer Progress Report 2016. Clinical Cancer Research, 2016, 22, S1-S137.	3.2	29
42	Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. Clinical Cancer Research, 2016, 22, 5362-5369.	3.2	73
43	Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?. Clinical Cancer Research, 2016, 22, 4963-4965.	3.2	3
44	WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Research, 2016, 18, 92.	2.2	56
45	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. Journal of Clinical Oncology, 2016, 34, 2925-2934.	0.8	538
46	â€œTake twoâ€? The role of second opinions for breast biopsy specimens. BMJ, The, 2016, 353, i3256.	3.0	1
47	The 21-gene recurrence score â€" biology remains at the forefront. Nature Reviews Clinical Oncology, 2016, 13, 470-472.	12.5	3
48	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€"Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal of Clinical Oncology, 2016, 34, 1689-1701.	0.8	243
49	Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prevention Research, 2016, 9, 2-10.	0.7	130
50	Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. Journal of Clinical Oncology, 2016, 34, 1580-1583.	0.8	26
51	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clinical Cancer Research, 2016, 22, 1130-1137.	3.2	166
52	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. Breast Cancer Research, 2015, 17, 133.	2.2	21
53	Can Circulating Tumor Cells Predict Resistance in Metastatic Breast Cancer?. Clinical Cancer Research, 2015, 21, 2421-2423.	3.2	9
54	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology, 2015, 33, 2563-2577.	0.8	783

#	Article	IF	Citations
55	Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clinical Cancer Research, 2015, 21, 5082-5091.	3.2	106
56	MCF-7 Cells--Changing the Course of Breast Cancer Research and Care for 45 Years. Journal of the National Cancer Institute, 2015, 107, djv073-djv073.	3.0	189
57	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. Journal of Clinical Oncology, 2015, 33, 2353-2360.	0.8	167
58	A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. Hormones and Cancer, 2015, 6, 214-224.	4.9	30
59	Tailoring therapiesâ€"improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546.	0.6	1,449
60	Expertise vs Evidence in Assessment of Breast Biopsies. JAMA - Journal of the American Medical Association, 2015, 313, 1109.	3.8	18
61	Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition. Cancer Prevention Research, 2015, 8, 1000-1009.	0.7	16
62	Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. Breast Cancer Research and Treatment, 2015, 153, 311-321.	1.1	20
63	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. Journal of Clinical Oncology, 2015, 33, 3938-3944.	0.8	223
64	The molecular landscape of premenopausal breast cancer. Breast Cancer Research, 2015, 17, 104.	2.2	56
65	Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). British Journal of Cancer, 2015, 113, 1651-1657.	2.9	43
66	Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Breast, 2015, 24, S120-S125.	0.9	15
67	Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene, 2015, 4, 129-141.	0.3	17
68	Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. New England Journal of Medicine, 2015, 372, 436-446.	13.9	588
69	Should We Embrace or Ablate Our Urge to (Ovarian) Suppress?. Journal of Clinical Oncology, 2014, 32, 3920-3922.	0.8	5
70	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2â€"Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 2014, 32, 3744-3752.	0.8	771
71	A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSFâ€"Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. Cancer Immunology Research, 2014, 2, 949-961.	1.6	77
72	Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer. Science Translational Medicine, 2014, 6, 229ra41.	5.8	72

#	Article	IF	Citations
73	Perspectives of Postmenopausal Breast Cancer Survivors on Adjuvant Endocrine Therapy-Related Symptoms. Oncology Nursing Forum, 2014, 41, 660-668.	0.5	27
74	Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response. Cancer Research, 2014, 74, 1463-1474.	0.4	122
75	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology, 2014, 32, 2959-2966.	0.8	1,080
76	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€“Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2014, 32, 2255-2269.	0.8	661
77	Epigenetic reprogramming in breast cancer: From new targets to new therapies. Annals of Medicine, 2014, 46, 397-408.	1.5	26
78	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2â€“Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 3307-3329.	0.8	210
79	Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. Breast Cancer Research and Treatment, 2014, 146, 99-108.	1.1	52
80	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 2100-2108.	0.8	165
81	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 2078-2099.	0.8	303
82	Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. Cellular and Molecular Life Sciences, 2014, 71, 1549.	2.4	14
83	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 2013, 24, 2206-2223.	0.6	2,805
84	Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. Breast, 2013, 22, S165-S170.	0.9	23
85	The search for ESR1 mutations in breast cancer. Nature Genetics, 2013, 45, 1415-1416.	9.4	62
86	Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. Carcinogenesis, 2013, 34, 2587-2592.	1.3	34
87	Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 961-965.	0.8	517
88	Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2â€positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer, 2013, 119, 2675-2682.	2.0	46
89	A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. Journal of the National Cancer Institute, 2013, 105, 701-710.	3.0	442
90	Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis, 2013, 34, 1196-1207.	1.3	98

#	Article	IF	Citations
91	Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer. Clinical Cancer Research, 2013, 19, 4008-4016.	3.2	26
92	Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial. Clinical Cancer Research, 2013, 19, 1281-1289.	3.2	52
93	Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831. Clinical Cancer Research, 2013, 19, 5798-5807.	3.2	21
94	Treatment for Breast Cancer: Is Time Really of the Essence?. Journal of the National Cancer Institute, 2013, 105, 80-82.	3.0	3
95	Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial. Journal of Clinical Oncology, 2013, 31, 2115-2122.	0.8	104
96	Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2013, 31, 2942-2962.	0.8	279
97	Integrated Proteomic and Metabolic Analysis of Breast Cancer Progression. PLoS ONE, 2013, 8, e76220.	1.1	24
98	Race and Hormone Receptorâ€“Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial. Journal of the National Cancer Institute, 2012, 104, 406-414.	3.0	89
99	Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. Journal of the National Cancer Institute, 2012, 104, 159-162.	3.0	68
100	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2736-2741.	3.3	95
101	Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer. Journal of Clinical Oncology, 2012, 30, 3051-3057.	0.8	83
102	Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells. Breast Cancer Research and Treatment, 2012, 136, 57-66.	1.1	40
103	Obesity at diagnosis is associated with inferior outcomes in hormone receptorâ€positive operable breast cancer. Cancer, 2012, 118, 5937-5946.	2.0	174
104	Hormonal therapy in breast cancer: A model disease for the personalization of cancer care. Molecular Oncology, 2012, 6, 222-236.	2.1	63
105	Hematopoietic growth factors: Personalization of risks and benefits. Molecular Oncology, 2012, 6, 237-241.	2.1	16
106	Novel Insight into KLF4 Proteolytic Regulation in Estrogen Receptor Signaling and Breast Carcinogenesis. Journal of Biological Chemistry, 2012, 287, 13584-13597.	1.6	30
107	Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Research and Treatment, 2012, 134, 683-692.	1.1	69
108	TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2012, 134, 751-757.	1.1	16

#	Article	IF	Citations
109	Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Research and Treatment, 2012, 131, 777-789.	1.1	110
110	Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Research and Treatment, 2012, 132, 175-187.	1.1	199
111	Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Research and Treatment, 2012, 131, 907-914.	1.1	62
112	A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Research and Treatment, 2012, 131, 915-924.	1.1	57
113	Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids, 2012, 42, 887-898.	1.2	78
114	Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.. Journal of Clinical Oncology, 2012, 30, 1005-1005.	0.8	28
115	Monoclonal Antibody Cocktail as an Enrichment Tool for Acetylome Analysis. Analytical Chemistry, 2011, 83, 3623-3626.	3.2	30
116	Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology, 2011, 29, 3366-3373.	0.8	646
117	Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4491-4497.	0.8	228
118	Epigenetics in breast cancer: what's new?. Breast Cancer Research, 2011, 13, 225.	2.2	114
119	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Research and Treatment, 2011, 127, 153-162.	1.1	15
120	C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2011, 29, 651-659.	0.8	64
121	Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer. Clinical Cancer Research, 2011, 17, 7194-7203.	3.2	20
122	Adjuvant Endocrine Therapy for Breast Cancer: Don't Ditch the Switch!. Journal of the National Cancer Institute, 2011, 103, 1280-1282.	3.0	5
123	American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer. Journal of Clinical Oncology, 2011, 29, 3939-3942.	0.8	59
124	Inhibition of Histone Deacetylases. Methods in Molecular Biology, 2011, 791, 297-311.	0.4	5
125	HER2-targeted therapies: how far we've come--and where we're headed. Oncology, 2011, 25, 425-6.	0.4	5
126	The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. Cancer Chemotherapy and Pharmacology, 2010, 65, 1067-1081.	1.1	34

#	Article	IF	Citations
127	Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Research and Treatment, 2010, 120, 581-592.	1.1	121
128	Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Research and Treatment, 2010, 124, 585-591.	1.1	73
129	Screening for therapeutic targets of vorinostat by SILACâ€based proteomic analysis in human breast cancer cells. Proteomics, 2010, 10, 1029-1039.	1.3	43
130	The American Society of Clinical Oncology Cancer Foundation Grants Program: A 25-Year Report and a Look Toward the Future. Journal of Clinical Oncology, 2010, 28, 1616-1621.	0.8	5
131	American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2010, 28, 3784-3796.	0.8	655
132	HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2010, 28, 4307-4315.	0.8	216
133	Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. Carcinogenesis, 2010, 31, 382-387.	1.3	68
134	Multiparametric Magnetic Resonance Imaging, Spectroscopy and Multinuclear (23Na) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer. Academic Radiology, 2010, 17, 1477-1485.	1.3	49
135	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncology, The, 2010, 11, 55-65.	5.1	1,252
136	Local Excision Alone Without Irradiation for Ductal Carcinoma In Situ of the Breast: A Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2009, 27, 5319-5324.	0.8	346
137	Reply to J.M. Guinebretiere and L. Arnould et al. Journal of Clinical Oncology, 2009, 27, 2734-2735.	0.8	1
138	The silent estrogen receptor--can we make it speak?. Cancer Biology and Therapy, 2009, 8, 485-496.	1.5	17
139	Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clinical Cancer Research, 2009, 15, 7693-7700.	3.2	23
140	Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factorâ€“Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation. Journal of Clinical Oncology, 2009, 27, 5911-5918.	0.8	217
141	Epigenetics meets estrogen receptor: regulation of estrogen receptor by direct lysine methylation. Endocrine-Related Cancer, 2009, 16, 319-323.	1.6	20
142	Small Beginnings: Do They Matter? The Importance of Lymphovascular Invasion in Early Breast Cancer. Journal of the National Cancer Institute, 2009, 101, 698-699.	3.0	1
143	Feasibility Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2816-2822.	0.8	15
144	Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Research and Treatment, 2009, 117, 443-451.	1.1	61

#	Article	IF	Citations
145	What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?. Current Oncology Reports, 2009, 11, 45-50.	1.8	12
146	What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?. Current Breast Cancer Reports, 2009, 1, 42-47.	0.5	0
147	Postoperative Endocrine Therapy for Invasive Breast Cancer. Cancer Treatment and Research, 2009, 151, 139-161.	0.2	4
148	Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. New England Journal of Medicine, 2008, 358, 1663-1671.	13.9	855
149	Prognostic Utility of the 21-Gene Assay in Hormone Receptorâ€“Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. Journal of Clinical Oncology, 2008, 26, 4063-4071.	0.8	312
150	A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. Clinical Cancer Research, 2008, 14, 6277-6283.	3.2	69
151	Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. Journal of Clinical Oncology, 2008, 26, 1948-1955.	0.8	176
152	Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells. Molecular Cancer Research, 2008, 6, 873-883.	1.5	143
153	Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology, 2008, 26, 4092-4099.	0.8	93
154	Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases. Clinical Cancer Research, 2008, 14, 1938-1946.	3.2	193
155	Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. Journal of Clinical Oncology, 2008, 26, 1231-1238.	0.8	485
156	Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory. Journal of Clinical Oncology, 2008, 26, 2473-2481.	0.8	212
157	Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. Journal of Clinical Oncology, 2007, 25, 2006-2011.	0.8	126
158	How We Maintain Bone Health in Early-Stage Breast Cancer Patients on Aromatase Inhibitors. Journal of Oncology Practice, 2007, 3, 323-325.	2.5	2
159	Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biology and Therapy, 2007, 6, 64-69.	1.5	143
160	Sulforaphane induces cell typeâ€“specific apoptosis in human breast cancer cell lines. Molecular Cancer Therapeutics, 2007, 6, 1013-1021.	1.9	289
161	Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis, 2007, 28, 1485-1490.	1.3	283
162	The maturation of medical oncology. Lancet Oncology, The, 2007, 8, 457-458.	5.1	5

#	Article	IF	Citations
163	Epigenetic Regulation as a New Target for Breast Cancer Therapy. Cancer Investigation, 2007, 25, 659-665.	0.6	72
164	Estrogen Receptor Î± Mediates Breast Cancer Cell Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death. Cancer Research, 2007, 67, 5337-5344.	0.4	94
165	Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. New England Journal of Medicine, 2007, 357, 2666-2676.	13.9	2,865
166	PI3 Kinase Activation and Response to Trastuzumab Therapy: What's neu with Herceptin Resistance?. Cancer Cell, 2007, 12, 297-299.	7.7	45
167	Aromatase inhibitors for breast cancer. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 215-228.	2.6	19
168	Epigenetic Regulation as a New Target for Breast Cancer Therapy. Translational Medicine Series, 2007, , 285-296.	0.0	0
169	Estrogen Carcinogenesis in Breast Cancer. New England Journal of Medicine, 2006, 354, 270-282.	13.9	1,531
170	Plasma Matrix Metalloproteinases 7 and 9 in Patients with Metastatic Breast Cancer Treated with Marimastat or Placebo: Eastern Cooperative Oncology Group Trial E2196. Clinical Breast Cancer, 2006, 6, 525-529.	1.1	8
171	Silencing estrogen receptor Î± in breast cancer cells. Cancer Biology and Therapy, 2006, 5, 848-849.	1.5	8
172	Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorganic and Medicinal Chemistry, 2006, 14, 3491-3495.	1.4	351
173	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Research and Treatment, 2006, 99, 295-300.	1.1	89
174	Adjuvant Hormonal Therapy for Premenopausal Women With Breast Cancer. Seminars in Oncology, 2006, 33, 657-663.	0.8	21
175	Polyamine Analogues Down-regulate Estrogen Receptor Î± Expression in Human Breast Cancer Cells. Journal of Biological Chemistry, 2006, 281, 19055-19063.	1.6	37
176	Still Waiting After 110 Years: The Optimal Use of Ovarian Ablation As Adjuvant Therapy for Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4949-4951.	0.8	6
177	Restoration of Tamoxifen Sensitivity in Estrogen Receptorâ€“Negative Breast Cancer Cells: Tamoxifen-Bound Reactivated ER Recruits Distinctive Corepressor Complexes. Cancer Research, 2006, 66, 6370-6378.	0.4	197
178	Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid. Clinical Cancer Research, 2006, 12, 3306-3310.	3.2	122
179	HER2Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology, 2006, 24, 3032-3038.	0.8	429
180	Epigenetic Biomarkers and Breast Cancer: Cause for Optimism. Clinical Cancer Research, 2006, 12, 6591-6593.	3.2	12

#	Article	IF	Citations
181	Myeloid Toxicity in Breast Cancer Patients Receiving Adjuvant Chemotherapy With Pegfilgrastim Support. Journal of Clinical Oncology, 2006, 24, 2392-2394.	0.8	21
182	Molecular mechanisms of polyamine analogs in cancer cells. Anti-Cancer Drugs, 2005, 16, 229-241.	0.7	73
183	Of Snail, mice, and women. Cancer Cell, 2005, 8, 173-174.	7.7	26
184	Protein Phosphatase 2A Regulates Estrogen Receptor Î± (ER) Expression through Modulation of ER mRNA Stability. Journal of Biological Chemistry, 2005, 280, 29519-29524.	1.6	39
185	Case 35-2005. New England Journal of Medicine, 2005, 353, 2177-2185.	13.9	3
186	Release of Methyl CpG Binding Proteins and Histone Deacetylase 1 from the Estrogen Receptor Î± (ER) Promoter upon Reactivation in ER-Negative Human Breast Cancer Cells. Molecular Endocrinology, 2005, 19, 1740-1751.	3.7	148
187	Increased Protein Stability Causes DNA Methyltransferase 1 Dysregulation in Breast Cancer. Journal of Biological Chemistry, 2005, 280, 18302-18310.	1.6	113
188	Sometimes a Great Notion--An Assessment of Neoadjuvant Systemic Therapy for Breast Cancer. Journal of the National Cancer Institute, 2005, 97, 159-161.	3.0	33
189	Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Nodeâ€“Positive, Steroid Hormone Receptorâ€“Positive Breast Cancer: Results From INT 0101 (E5188). Journal of Clinical Oncology, 2005, 23, 5973-5982.	0.8	221
190	Spermine Oxidase SMO(PAOh1), Not N1-Acetylpolyamine Oxidase PAO, Is the Primary Source of Cytotoxic H2O2 in Polyamine Analogue-treated Human Breast Cancer Cell Lines. Journal of Biological Chemistry, 2005, 280, 39843-39851.	1.6	99
191	Role of p53/p21Waf1/Cip1 in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells. Cancer Biology and Therapy, 2005, 4, 1006-1013.	1.5	17
192	Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. Journal of the National Cancer Institute, 2005, 97, 1262-1271.	3.0	1,048
193	Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. New England Journal of Medicine, 2005, 353, 1673-1684.	13.9	4,956
194	Epigenetic regulation of protein phosphatase 2A (PP2A), Lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer Biology and Therapy, 2004, 3, 1304-1312.	1.5	30
195	What Is the Role of Ovarian Ablation in the Management of Primary and Metastatic Breast Cancer Today?. Oncologist, 2004, 9, 507-517.	1.9	36
196	Multiparametric and Multinuclear Magnetic Resonance Imaging of Human Breast Cancer: Current Applications. Technology in Cancer Research and Treatment, 2004, 3, 543-550.	0.8	41
197	Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology, 2004, 22, 3700-3704.	0.8	120
198	Deja Vu for Breast Cancer Two?. Journal of the National Cancer Institute, 2004, 96, 497-499.	3.0	3

#	Article	IF	Citations
199	Induction of spermidine/spermine N 1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N 1,N 11-diethylnorspermine. Cancer Chemotherapy and Pharmacology, 2004, 54, 122-126.	1.1	27
200	Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196. Journal of Clinical Oncology, 2004, 22, 4683-4690.	0.8	218
201	Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cells. Molecular Cancer Research, 2004, 2, 81-8.	1.5	12
202	Trastuzumab in breast cancer. Oncology, 2004, 18, 1117-28; discussion 1131-2, 1137-8.	0.4	23
203	Regulation of Polyamine Analogue Cytotoxicity by c-Jun in Human MDA-MB-435 Cancer Cells. Molecular Cancer Research, 2004, 2, 81-88.	1.5	32
204	A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor Î± (ER) in ER negative human breast cancer cells in combination with 5-aza 2â€²-deoxycytidine. Breast Cancer Research and Treatment, 2003, 81, 177-186.	1.1	160
205	Methyl-group dietary intake and risk of breast cancer among African-American women: a caseâ€“control study by methylation status of the estrogen receptor alpha genes. Cancer Causes and Control, 2003, 14, 827-836.	0.8	48
206	New findings about endocrine therapy for breast cancer. Breast, 2003, 12, 368-372.	0.9	2
207	The follow-up of breast cancer. Seminars in Oncology, 2003, 30, 338-348.	0.8	56
208	The biology of breast carcinoma. Cancer, 2003, 97, 825-833.	2.0	181
209	Design, Synthesis, and Evaluation of Novel Boronic-Chalcone Derivatives as Antitumor Agents. Journal of Medicinal Chemistry, 2003, 46, 2813-2815.	2.9	281
210	A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. New England Journal of Medicine, 2003, 349, 1793-1802.	13.9	1,723
211	Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of Clinical Oncology, 2003, 21, 1431-1439.	0.8	1,464
212	Specific Inhibition of DNMT1 by Antisense Oligonucleotides Induces Re-expression of Estrogen Receptor a (ER) in ER-negative Human Breast Cancer Cell Lines. Cancer Biology and Therapy, 2003, 2, 552-556.	1.5	84
213	A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. Clinical Cancer Research, 2003, 9, 2769-77.	3.2	52
214	A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clinical Cancer Research, 2003, 9, 5922-8.	3.2	79
215	Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831. Journal of the National Cancer Institute, 2002, 94, 855-857.	3.0	374
216	Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet, The, 2001, 357, 1335-1336.	6.3	324

#	Article	IF	Citations
217	Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. Journal of Mammary Gland Biology and Neoplasia, 2001, 6, 183-192.	1.0	71
218	Use of SERMs for the Adjuvant Therapy of Earlyâ€Stage Breast Cancer. Annals of the New York Academy of Sciences, 2001, 949, 80-88.	1.8	6
219	Ovarian ablation as adjuvant therapy for breast cancer. Seminars in Oncology, 2001, 28, 322-331.	0.8	19
220	Primary Systemic Therapy in Operable Breast Cancer. Journal of Clinical Oncology, 2000, 18, 1558-1569.	0.8	84
221	American Society of Clinical Oncology 1998 Update of Recommended Breast Cancer Surveillance Guidelines. Journal of Clinical Oncology, 1999, 17, 1080-1080.	0.8	237
222	Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells. Oncogene, 1999, 18, 7453-7461.	2.6	35
223	THE BIOLOGY OF BREAST CANCER. Hematology/Oncology Clinics of North America, 1999, 13, 311-332.	0.9	33
224	Apoptosis and Breast Cancer. , 1999, , 291-303.		4
225	The loss of estrogen and progesterone receptor gene expression in human breast cancer. Journal of Mammary Gland Biology and Neoplasia, 1998, 3, 85-94.	1.0	160
226	Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. Oncogene, 1998, 17, 577-583.	2.6	37
227	The regulation of estrogen receptor expression and function in human breast cancer. Cancer Treatment and Research, 1998, 94, 255-278.	0.2	9
228	Role of Estrogen Receptor Gene Demethylation and DNA MethyltransferaseÂ·DNA Adduct Formation in 5-Aza-2â€²deoxycytidine-induced Cytotoxicity In Human Breast Cancer Cells. Journal of Biological Chemistry, 1997, 272, 32260-32266.	1.6	132
229	Apoptosis in Hormone-Responsive Malignancies. Advances in Pharmacology, 1997, 41, 553-583.	1.2	8
230	Regulation of Estrogen Receptor Î± Function in Breast Cancer. Critical Reviews in Oncogenesis, 1997, 8, 29-46.	0.2	36
231	Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genetics, 1994, 7, 536-540.	9.4	1,112
232	Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Research and Treatment, 1993, 28, 277-284.	1.1	11
233	Sixteen-Week Dose-Intense Chemotherapy in the Adjuvant Treatment of Breast Cancer. Journal of the National Cancer Institute, 1990, 82, 570-574.	3.0	42
234	Expression of Transforming Growth Factor Î± and its Messenger Ribonucleic Acid in Human Breast Cancer: Its Regulation by Estrogen and its Possible Functional Significance. Molecular Endocrinology, 1988, 2, 543-555.	3.7	413

#	Article	IF	Citations
235	Epidermal Growth Factor Receptor Gene Expression in Estrogen Receptor-Positive and Negative Human Breast Cancer Cell Lines. Molecular Endocrinology, 1987, 1, 216-223.	3.7	258